Background The alarming increase in drug resistance and decreased production of new antibiotics necessitate the evaluation of combinations of existing antibiotics. Fosfomycin shows no cross-resistance to other antibiotic classes. Thus, its combination with other antibiotics may potentially show synergy against resistant bacteria. Objective To evaluate the available published evidence regarding the in vitro synergistic activity of fosfomycin with other antibiotic agents against Gram-positive and Gramnegative bacteria. Methods PubMed and the Cochrane Library were searched. Results Forty-one studies, including 34 (82.9%) conducted/ published before 2000, were eligible for inclusion. The relatively limited number of isolates examined and the considerable heterogeneity of the retrieved studies regarding the definitions of synergy and the methodologies used hamper conclusive remarks for specific combinations of fosfomycin with other antibiotics. Yet, in the 27 studies providing data for Gram-positive strains (16 for Staphylococcus aureus, 3 for coagulase-negative staphylococci, 5 for Streptococcus pneumoniae, and 3 for Enterococcus spp.), fosfomycin showed synergy against methicillin-resistant Staphylococcus aureus when combined with cefamandole, cephazolin, ceftriaxone, ciprofloxacin, imipenem, and rifampicin. Data regarding Gram-negative strains reported from 15 studies (12 exclusively for P. aeruginosa, 2 exclusively for Enterobacteriaceae, 1 for both, and 1 for Acinetobacter baumannii) suggested that fosfomycin showed an estimable synergistic effect with gentamicin, amikacin, ceftazidime, cefepime, ciprofloxacin, levofloxacin, and aztreonam against P. aeruginosa. Conclusions The synergistic combination of fosfomycin with other antibiotics may be a useful alternative treatment option for Gram-negative and Gram-positive infections. Additional studies using more stringent definitions of synergy, and studies reporting on the clinical efficacy of fosfomycin combinations in the current era of high antimicrobial resistance are needed.
Introduction
The alarmingly increasing drug resistance rates observed in our era limit our armamentarium of antibiotics and necessitate the development and evaluation of alternative ways to cope with this issue. Specifically, the renewal of physicians' interest in older and neglected antibiotic agents [1, 2] , as well as the use of combinations of antibiotic agents for the treatment of patients with infections may be useful "weapons" in the "battle" against antimicrobial resistance.
Fosfomycin is an old antibiotic agent that has been used for the treatment of uncomplicated urinary tract infections in many clinical settings [3, 4] . Additionally, data reported from recent studies encourage the use of fosfomycin for the treatment of infections beyond the urinary tract [5, 6] as well as for infections due to specific categories of resistant bacteria [7, 8] . Consequently, a potential synergistic activity of fosfomycin with other antibiotic agents may prove to be an important issue with considerable clinical implications.
In this regard, we aimed to collect and evaluate the available evidence regarding the in vitro synergistic activity of fosfomycin in combination with other antibiotic agents against Gram-negative and Gram-positive bacteria.
Methods

Literature search
We searched the PubMed and the Cochrane Library databases. The search strategy applied to these databases was "(fosfomycin OR phosphomycin OR phosphonomycin) AND (synergy OR synergism OR combination OR antagonism)." Bibliographies of relevant articles were also hand-searched.
Study selection criteria
A study was considered as eligible for inclusion if it provided data regarding the in vitro use of fosfomycin in combination with other antibiotic agents against Grampositive and/or Gram-negative microbial strains. Studies written in languages other than English, Spanish, French, German, Italian, or Dutch were excluded. Abstracts from scientific conferences were also excluded.
Data extraction
We extracted data regarding the laboratory methods used, the fosfomycin break point, the susceptibility of the pathogens to fosfomycin, the pathogens isolated, the site of isolation, and the type of antibiotics used in the combined therapy. Data regarding the number of bacterial strains for which synergism between fosfomycin and other selected antibiotic agents was observed were also extracted.
Results
Selected studies
Our searches performed in PubMed and the Cochrane Library generated a total of 411 and 36 articles, respectively. Among these, 41 studies were considered eligible for inclusion in our review .
Characteristics of the included studies
Twenty-seven of the 41 included studies provided data regarding the number of Gram-positive strains for which a synergistic effect of fosfomycin with other selected antibiotic agents was exhibited [10, 13, 15, 19, 21, 23-26, 28-33, 35-44, 46, 47] . Fifteen of the 41 included studies provided data regarding the number of Gram-negative strains for which a synergistic effect of fosfomycin with other selected antibiotic agents was exhibited [9, 11, 12, 14, 16-18, 20, 22, 27, 34, 45, 47-49] . One of the 41 included studies provided data regarding the number of Gram-positive as well as Gram-negative strains for which a synergistic effect of fosfomycin with other selected antibiotic agents was exhibited [47] .
The definition of synergy used by the majority of the included studies (25 of the 41 included) was the fractional inhibitory concentration index (FICI), represented by the formula FICI=(MIC of fosfomycin in combination/MIC of fosfomycin alone)+(MIC of the antibiotic in combination/ MIC of the antibiotic alone), where MIC is the minimal inhibitory concentration. The efficacy time index (ETI) technique was also used in two of the included studies for the assessment of the synergistic effect of fosfomycin with the evaluated antibiotics [13, 14] . Detailed data regarding the laboratory methods used, the fosfomycin break points, the definition of synergy used, the antibiotics evaluated, as well as the pathogens evaluated along with the site of isolation are presented, when available, in Table 1 .
Synergy of fosfomycin with other antibiotics
Gram-positive strains
Thirteen studies provided data regarding the in vitro synergistic effect of fosfomycin with other antibiotics against MRSA strains [13, 19, 26, 29-31, 36, 41-44, 46] . The study examining the largest number of MRSA strains reported a good synergistic effect of fosfomycin with cefamandole and with methicillin (65.5 and 31% of the 148 tested strains, respectively) [42] . However, the findings of this study were not encouraging regarding the potential synergistic effect of fosfomycin with gentamicin, trimethoprim, and vancomycin [42] . Two other studies providing data for a considerable number of MRSA strains reported a synergistic effect of 100% for the combination of fosfomycin with cefamandole [44] , and a synergistic effect of 94.2% for the combination of fosfomycin with cefazolin [31] . Encouraging relevant data were also reported from Table 2 . Nine studies provided data regarding the in vitro synergistic effect of fosfomycin with other antibiotics against Staphylococcus aureus and/or other coagulasenegative Staphylococcus strains [29, 32, [35] [36] [37] [38] [39] [40] 47] ; specific data are shown in Table 2 . Notably, a synergistic effect of fosfomycin with ciprofloxacin was reported for 51.3% of the 37S. aureus tested strains [38] . The findings regarding gentamicin were discouraging (0 of the 29S. aureus tested strains) [47] . Relevant data regarding Streptococcus spp. were reported from five studies [21, 23, 25, 28, 37] . A similar synergistic effect of fosfomycin was reported with penicillin [21] , cefminox [21] , cefotaxime [28] , and cefotiam [21] . Specific data are shown in Table 2 .
Three studies provided data regarding the in vitro synergistic effect of fosfomycin with other antibiotics against Enterococcus spp. [24, 33, 39] . A synergistic effect of 90% was reported for the combination of fosfomycin with cefotaxime from a study analyzing a total of 50 strains [24] . Data regarding the combination of fosfomycin with daptomycin [33] or imipenem [39] were also encouraging.
Gram-negative strains
Thirteen studies provided data regarding the in vitro synergistic effect of fosfomycin with other antibiotics against Pseudomonas aeruginosa strains [9, 11, 12, 14, 16-18, 20, 27, 34, 38, 45, 47] . In one of the abovementioned studies providing data for 30 P. aeruginosa strains [14] , fosfomycin exhibited a synergistic effect in≥ 70% of the tested strains when it was used in combination with aztreonam, cefepime, ceftazidime, gentamicin, imipenem, and levofloxacin. Two other studies evaluated the potential synergistic effect of fosfomycin with ciprofloxacin, reporting data for 74 and 37 P. aeruginosa strains, respectively; the observed synergistic effect was 27% [9] and 78.4% [38] , respectively. Three other studies evaluated the potential synergistic effect of fosfomycin with amikacin against P. aeruginosa [17, 20, 27 ] . The observed synergistic effect ranged from 18.8 to 100%. Yet, the number of the analyzed strains in each of these four studies was limited (maximum 26 strains).
A single study provided data regarding the potential synergistic effect of fosfomycin against a total of 34 Acinetobacter baumannii strains [22] . Specific data are shown in Table 3 . Another study provided data regarding the synergistic effect of fosfomycin with gentamicin against Escherichia coli and Klebsiella spp. [47] . Specific data are shown in Table 3 . Yet, the number of the evaluated strains was limited-30 and 12 strains, respectively. Data regarding Salmonella and Shigella strains were also reported in this study [47] . A synergistic effect for the combination of fosfomycin with amikacin was observed in 82.2% of the 90 evaluated Salmonella strains. Data regarding the synergistic effect of fosfomycin with carbenicillin and gentamicin against Serratia marcescens were provided in two studies [47, 49] . The findings were discordant; specific data are shown in Table 3 .
Discussion
The findings of our study imply that the combination of fosfomycin with other antibiotic agents may provide a useful alternative regarding the treatment of patients with Gram-negative or Gram-positive infections, including MRSA infection. However, the evaluated in vitro data, generated mainly from old studies, do not prove directly the in vitro synergism of fosfomycin with other antibiotic agents against the above-mentioned infections. Additionally, the considerable heterogeneity among the included studies regarding the definition of synergy and the methodology used hampers the establishment of firm conclusions, as well as the extrapolation of the in vitro findings into clinical practice.
Fosfomycin is an antibiotic agent that has been mainly used for the treatment of urinary tract infections. Specifically, fosfomycin tromethamine is approved as an oral single-dose treatment for acute uncomplicated cystitis [50] . Moreover, fosfomycin may also be a useful treatment option for specific types of resistant uropathogens that exhibit considerably high rates of resistance due to the production of extended spectrum beta-lactamases (ESBLs) [51, 52] . However, recent studies suggest that mutations occurring among populations of uropathogens and specifically among populations of ESBL producers may result in the emergence of resistance to fosfomycin [53, 54] . Indeed, the issue of emergence of resistance is one of significant importance regarding fosfomycin treatment. Resistance of fosfomycin may be attributed to several chromosomal mutations, which mainly affect its uptake [55] . As a result, the potential of a synergistic effect of fosfomycin with another antibiotic agent is an issue of importance, both at a patient and at a community level.
According to a recently published review, pharmacokinetic and pharmacodynamic aspects of fosfomycin, such as the limited binding with serum proteins, the unchanged excretion in the urine, along with the relatively high concentrations that it achieves in the urine, serum, lung, cerebrospinal fluid, and other sites, favor its use for the treatment of relevant infections [56] . Regarding the potential synergistic effect of fosfomycin with other antibiotic agents, fosfomycin appears to have potentially useful pharmacokinetic/pharmacodynamic aspects that favor its use in combination with other antibiotic agents for the treatment of specific infections. In brief, the ability of [39] n/N Number of isolates exhibiting synergism between fosfomycin and the examined antimicrobial agent/total number of isolates examined in the included study a In cases where fewer than 10 bacterial strains were evaluated, percentages are not displayed in the table fosfomycin to modify the production of penicillin-binding proteins (PBPs) enables its use for the treatment of MRSA infections as well as infections from penicillin-resistant S. pneumoniae [23, 41] . The ability of fosfomycin to penetrate biofilm layers encourages the use of fosfomycin in combination with other antibiotics against microbial strains growing on biofilms. Specifically, relevant studies report a synergistic effect of fosfomycin with quinolone antibiotic agents such as ulifloxacin, levofloxacin [11] , and ofloxacin against P. aeruginosa biofilm isolates [57] . Notably, fosfomycin is synergistic with N-acetylocysteine against E. coli biofilm isolates [58] .
Another aspect of fosfomycin that could prove useful, when it is used in combination with other antibiotic agents, is its ability to modify the toxicity of many types of coadministered drugs [56] . Specifically, fosfomycin is reported to mitigate in vivo the toxicity of aminoglycosides [59] , glycopeptides [60] , as well as polymyxin B [61] . Finally, it has been reported that the synergistic combination with either amoxicillin or clarithromycin may provide a useful alternative treatment option for patients with Helicobacter pylori infections [62] .
Our study has limitations that should be taken into consideration before the extrapolation of our findings. Firstly, considerable heterogeneity is observed among the included studies regarding the definition of synergy; specifically only 25 of the 41 studies used the fractional inhibitory concentration index as the definition of synergy of fosfomycin with the respective evaluated antibiotics. Heterogeneity was also observed regarding the laboratory [48] n/N Number of isolates exhibiting synergism between fosfomycin and the examined antimicrobial agent/total number of isolates examined in the included study. a In cases where fewer than 10 bacterial strains were evaluated, percentages are not displayed in the table methods, as well as the fosfomycin break points used. Moreover, the majority (34 of the 41) of the included studies were older studies, published during the period 1977-1999. In this regard, we were unable to reach conclusive results regarding specific antibiotic combinations with fosfomycin for the evaluated microorganisms. Despite these shortcomings, the available data are not to be overlooked as they indicate that further research is justified.
In conclusion, in this era of alarmingly high drug resistance, the synergistic combination of fosfomycin with several other antibiotic agents may be a useful alternative treatment option for Gram-negative and Gram-positive infections. However, additional studies with more stringent definitions, as well as studies that will evaluate the clinical efficacy of synergistic combinations of fosfomycin with other antibiotics will contribute to the already available knowledge regarding the role of fosfomycin in synergistic combinations with other antibiotics.
Funding None
Conflict of interest None
